Zhou viewpoint: the new covid-19 pneumonia diagnosis and treatment plan is released, focusing on investment opportunities in the industrial chain
In March 15th, the National Health Council released the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth). The new diagnosis and treatment plan adds antigen detection in the diagnosis part and some drugs in the treatment part, further enriching China’s epidemic prevention tool library, and relevant fields are expected to benefit.
Antigen detection has a wide range of application scenarios, and a variety of antigen detection products in China have been approved. At present, 17 covid-19 antigen self-test products have been listed in China. Enterprises with first mover advantages, channel advantages, production capacity advantages and quality advantages are expected to obtain greater benefits. It is suggested to pay attention to Guangzhou Wondfo Biotech Co.Ltd(300482) , Zhejiang Orient Gene Biotech Co.Ltd(688298) , Asahi biology, etc.
Covid-19 small molecular weight is imminent, and China’s R & D is advancing in an orderly manner. Moshadong molnupiravir and Pfizer paxlovid have been approved in many countries around the world. Commercial products and MPP products are expected to bring huge benefits to the industrial chain. The research and development of small molecule drugs in China is mainly based on RdRp and 3clpro inhibitors. The real biological azvudine and Shanghai Junshi Biosciences Co.Ltd(688180) vv116 are expected to be approved for listing this year. Covid-19 a small molecule: a small molecule: a small molecule: a small molecule: a small molecule: a small molecule: an upstream cdmo for a small molecule: a small molecule: the cdmo for a small molecule: it’s recommended to pay attention to the recommendations for the cdmo of the upstream cdmo for a small molecule. The cdmo for the upstream cdmo for a small molecule: a small molecule: a small molecule: an upstream cdmo for a small molecule: the cdmo for the upstream of a small molecule: it’s recommended to pay attention to the .
Timely, comprehensive and in-depth intervention of traditional Chinese medicine to help epidemic prevention. In the recent release of the new version and the expert consensus on the prevention and treatment of New Coronavirus pneumonia in proprietary Chinese medicine, according to the severity of the disease, stages and symptoms of traditional Chinese medicine, we recommend different Chinese medicine for treatment. It is suggested to pay attention to Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) , Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) , Chinese traditional medicine.
Market review: the biomedical sector rose steadily this week, rising 1.08%, ranking third in all SW primary industries. Since the beginning of this year, pharmaceutical biology has fallen by 12.52%, outperforming the CSI 300 index by 1.14 percentage points, ranking 16th in all SW primary industries. In terms of subdivided industries, the pharmaceutical and biological subdivided sectors rose more or less this week, biological products rose by 6.29%, and medical services fell the most, down 1.16%. Since the beginning of this year, the performance of chemical raw materials has been the best, with an increase of 2.45% year to date; Medical services was the weakest performing sub sector, down 20.45%. Traditional Chinese medicine (- 12.98%) and medical services (- 20.45%) underperformed the pharmaceutical and biological (SW) industry index.
In terms of performance of individual stocks, the top five stocks that rose last week were: China Meheco Group Co.Ltd(600056) (58.91%), Pku Healthcare Corp.Ltd(000788) (41.13%), Walvax Biotechnology Co.Ltd(300142) (30.96%), Jiangxi Synergy Pharmaceutical Co.Ltd(300636) (28.45%) and Zhejiang Ausun Pharmaceutical Co.Ltd(603229) (27.76%). The top five stocks with declines are: Zhejiang Orient Gene Biotech Co.Ltd(688298) (- 15.47%), Changjiangrunfa Health Industry Co.Ltd(002435) (- 15.35%), Yixintang Pharmaceutical Group Co.Ltd(002727) (- 14.65%), Nanjing Vishee Medical Technology Co.Ltd(688580) (- 13.13%) and Aier Eye Hospital Group Co.Ltd(300015) (- 11.97%).
Valuation: this week’s valuation showed a slight upward trend. As of Friday (March 18), PE (TTM) and Pb (LF) of the whole pharmaceutical and biological (SW) industry were 31.0 times and 3.78 times respectively.
Risk warning: risk of R & D failure; Risk of orders and product sales falling short of expectations; The risk that the capacity expansion is less than expected; Covid-19 epidemic development exceeds the expected risk; Risk of product price reduction exceeding expectations.
